Franklin Resources Inc. Sells 118,900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Franklin Resources Inc. cut its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 17.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 579,636 shares of the company’s stock after selling 118,900 shares during the period. Franklin Resources Inc. owned approximately 3.86% of Jasper Therapeutics worth $10,903,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its stake in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after buying an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in Jasper Therapeutics in the 3rd quarter valued at $59,000. Fernwood Investment Management LLC grew its stake in shares of Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after acquiring an additional 3,427 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective on the stock. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $73.38.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $21.57 on Friday. The company has a 50 day simple moving average of $21.63 and a two-hundred day simple moving average of $20.76. Jasper Therapeutics, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $31.01. The company has a market capitalization of $323.57 million, a price-to-earnings ratio of -4.55 and a beta of 2.18.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.